| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 16, 2025
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...
Nov 16, 2024Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...